Effect of Amino Acid Peritoneal Dialysis Solution on Low Protein Treatment in Peritoneal Dialysis Patients

Peritoneal dialysis (PD) is one of the commonly used treatments for patients with end-stage renal disease (ESRD). Despite technological advances, mortality rates in patients with PD remain high. Nutritional status is an important factor affecting the prognosis of PD patients; low protein, as a complication of PD patients after dialysis, may lead to malnutrition, oedema of both lower limbs or whole body, decreased immunity, aggravation of the condition and other adverse consequences. It will also increase the mortality rate of patients and increase the incidence of cardiovascular and cerebrovascular diseases, which is considered to be the main limiting factor of PD. As a substitute for traditional glucose dialysate, Amino Acid Deritoneal Dialysate (AAD) stimulates protein synthesis by increasing amino acid availability in PD patients and inducing hyperamino acidemia due to its sugar-free and good biocompatibility. Based on literature retrieved from PubMed, Web of Science and Scopus, we found that AAD can not only effectively improve the nutritional status of PD patients, but also effectively alleviate the complications of low protein caused by traditional dialysate. Although AAD has shown promise in the treatment of low-protein patients, further randomized controlled trials are needed to verify its long-term efficacy and safety. AAD provides a new treatment option for patients with low protein, which has vital clinical significance.